Expert Interview
Examining the phase 2 result of Vaxcyte’s VAX-24 for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64
Ticker(s): PCVXInstitution: RWJ Barabas Health
- Board certified critical care medicine at RWJ Barabas Health
- Currently manages 30 patients with central venous catheters that have developed a CRBSI or CLABSI
- Familiar with the results from the Phase 2b trial which assessed the safety and efficiency of Mino-Lok to salvage central venous catheters from catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs)
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
